Lynn A Jansen
Biographic Data
| ID | 6763538 |
|---|---|
| NAME | Lynn A Jansen |
| GIVEN NAMES | Lynn A |
| FAMILY NAME | Jansen |
| SIGNATURE | JANSEN L A |
| AFFILIATIONS | Saint Vincent's Catholic Medical Center |
| ORCID | 0000-0001-6707-335X |
| VERIFIED | Yes |
| TOTAL WORKS | 6 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 6 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2003 |
| LATEST PUBLICATION YEAR | 2021 |
| H-INDEX | 0 |
Weighted Lotteries and the Allocation of Scarce Medications for Covid‐19
The allocation of vaccines and therapeutics for Covid‐19 obviously raises ethical questions, and physicians and ethicists have begun to address them. Writers have identified various criteria that should guide allocation decisions, but the criteria often conflict and need to be balanced against one another. This article proposes a model for thinking about how different considerations that are relevant to the distribution of vaccines and scarce tre…
Variations in Unrealistic Optimism Between Acceptors and Decliners of Early Phase Cancer Trials
Research has found that patient-subjects in early phase cancer trials exhibit unrealistic optimism regarding the risks and possible benefits of trial participation. Unrealistic optimism is associated with therapeutic misconception and failures to appreciate research-related information. This is the first study to assess whether those who decline to participate in these trials also exhibit unrealistic optimism. It is also the first study to assess…
Mindsets, Informed Consent, and Research
Cancer patients presented with the option to participate in early-phase cancer trials confront a very difficult choice. Standard therapeutic interventions have proven unsuccessful, but the prospect for significant therapeutic benefit from participating in these trials is very low. Yet there is some question whether the patients appreciate just how difficult the choice is. When patients who decide to participate in such trials are asked later to e…
A Closer Look at the Bad Deal Trial
Local IRBs, Multicenter Trials, and the Ethics of Internal Amendments
ocal Institutional Review Boards (IRBs) are increasingly asked to review research protocols that are part of a larger multicenter study. Typically, but not always, these studies are funded by private industry, with the intent to test a drug or mechanical device for approval by the Food and Drug Administration (FDA). Although IRBs at some sites approve protocols for these studies, IRBs at other sites may be unwilling to do so. For example, an IRB …
Bioethics, Conflicts of Interest, the Limits of Transparency
The movement in bioethics toward disclosure of financial conflicts of interest is well and good, most of the time. But in some cases, disclosure is not only unnecessary but destructive. When bioethicists advance arguments whose premises and logical moves are open to scrutiny, disclosure--far from clearing the air of bias introduces bias. Over the past several years, there has been growing concern about the commercialization of bioethics. As ever …
No prominent works on this page.
Bioethics, Conflicts of Interest, the Limits of Transparency
The movement in bioethics toward disclosure of financial conflicts of interest is well and good, most of the time. But in some cases, disclosure is not only unnecessary but destructive. When bioethicists advance arguments whose premises and logical moves are open to scrutiny, disclosure--far from clearing the air of bias introduces bias. Over the past several years, there has been growing concern about the commercialization of bioethics. As ever …
A Closer Look at the Bad Deal Trial
Local IRBs, Multicenter Trials, and the Ethics of Internal Amendments
ocal Institutional Review Boards (IRBs) are increasingly asked to review research protocols that are part of a larger multicenter study. Typically, but not always, these studies are funded by private industry, with the intent to test a drug or mechanical device for approval by the Food and Drug Administration (FDA). Although IRBs at some sites approve protocols for these studies, IRBs at other sites may be unwilling to do so. For example, an IRB …
Mindsets, Informed Consent, and Research
Cancer patients presented with the option to participate in early-phase cancer trials confront a very difficult choice. Standard therapeutic interventions have proven unsuccessful, but the prospect for significant therapeutic benefit from participating in these trials is very low. Yet there is some question whether the patients appreciate just how difficult the choice is. When patients who decide to participate in such trials are asked later to e…
Variations in Unrealistic Optimism Between Acceptors and Decliners of Early Phase Cancer Trials
Research has found that patient-subjects in early phase cancer trials exhibit unrealistic optimism regarding the risks and possible benefits of trial participation. Unrealistic optimism is associated with therapeutic misconception and failures to appreciate research-related information. This is the first study to assess whether those who decline to participate in these trials also exhibit unrealistic optimism. It is also the first study to assess…
Weighted Lotteries and the Allocation of Scarce Medications for Covid‐19
The allocation of vaccines and therapeutics for Covid‐19 obviously raises ethical questions, and physicians and ethicists have begun to address them. Writers have identified various criteria that should guide allocation decisions, but the criteria often conflict and need to be balanced against one another. This article proposes a model for thinking about how different considerations that are relevant to the distribution of vaccines and scarce tre…
Ethics in Clinical Research (4 works) · Medicine (4 works) · Health Systems, Economic Evaluations, Quality of Life (3 works) · Political science (3 works) · Psychology (3 works) · Biomedical Ethics and Regulation (2 works) · Clinical trial (2 works) · Ethics in medical practice (2 works) · Internal Medicine (2 works) · Law (2 works)